期刊
JOURNAL OF CANCER
卷 12, 期 19, 页码 5888-5894出版社
IVYSPRING INT PUBL
DOI: 10.7150/jca.60170
关键词
Serine hydroxymethyltransferase 2 (SHMT2); human carcinogenesis; predictive biomarker; cell proliferation; tumour growth
类别
资金
- National Natural Science Foundation of China [81802885, 81820108023]
- National Key Research and Development Program of China [2018YFC1705505]
- Priority Academic Program Development of Jiangsu Higher Education Institutions
Cellular metabolic reprogramming has been recognized as a hallmark of human cancer, with SHMT2 playing a crucial role in supporting tumor growth in various human malignancies. Elevated expression of SHMT2 is associated with poor prognosis, highlighting its potential as a prognostic marker and target for anticancer therapies.
In the last few years, cellular metabolic reprogramming has been acknowledged as a hallmark of human cancer and evaluated for its crucial role in supporting the proliferation and survival of human cancer cells. In a variety of human tumours, including hepatocellular carcinoma (HCC), breast cancer and non-small-cell lung cancer (NSCLC), a large amount of carbon is reused in serine/glycine biosynthesis, accompanied by higher expression of the key glycine synthetic enzyme mitochondrial serine hydroxymethyltransferase 2 (SHMT2). This enzyme can convert serine into glycine and a tetrahydrofolate-bound one-carbon unit, ultimately supporting thymidine synthesis and purine synthesis and promoting tumour growth. In tumour samples, elevated expression of SHMT2 was found to be associated with poor prognosis. In this review, the pivotal roles of SHMT2 in human carcinogenesis are described, highlighting the underlying regulatory mechanisms through promotion of tumour progression. In conclusion, SHMT2 may serve as a prognostic marker and a target for anticancer therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据